Generating a T cell tumor-specific immune response in vivo: Can flt3- ligand-generated dendritic cells tip the balance?

Cancer Immunology Immunotherapy

Volumn 48, Issue 6, 1999, Pages 281-286

  McKenna, H J ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; LIGAND; TUMOR ANTIGEN;

CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR REJECTION;

ANIMALS; ANTIGEN PRESENTATION; CELL DIVISION; DENDRITIC CELLS; FIBROSARCOMA; FORECASTING; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MEMBRANE PROTEINS; MICE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032883179     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050576     Document Type: Review

References (69)

1. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB (1998) Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 4:1321
2. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177
3. Avradopoulos K, Mehta S, Blackinton D, Wanebo HJ (1997) Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol 4:184
4. Bevan MJ (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143:1283
5. Bianchi R, Grohmann U, Belladonna ML, Silla S, Fallarino F, Ayroldi E, Fioretti MC, Puccetti P (1996) IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J Immunol 157:1589
6. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337
7. Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N (1998) Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 35:1
8. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams De, Lyman SD (1996) Hematologic effects of flt3 ligand in vivo in mice. Blood 88:2004
9. Brasel J, McKenna HJ, Charrier K, Morrissey PJ, Williams DE, Lyman SD (1997) Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice. Blood 90:3781
10. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80:1198
11. Carbone FR, Kurts C, Bennett SR, Miller JF, Heath WR (1998) Cross-presentation: a general mechanism for CTL immunity and tolerance. Immunol Today 19:368
12. Caux C, Dezutter-Dambuyant C, Schmitt D, Bancherau J (1992) GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360:258
13. Chang HL, Gillett N, Figari I, Lopez AR, Palladino MA, Derynck R (1993) Increased transforming growth factor beta expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumor growth of Meth A sarcoma cells. Cancer Res 53:4391
14. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K (1997) Anti-tumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57:3511
15. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I, Hellstrom KE (1994) Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179:523
16. Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE (1997) Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89:1133
17. Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF (1999) Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93:780
18. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58:380
19. + T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J Immunol 162:609
20. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L (1999) Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo (in Process Citation). Nat Med 5:405
21. Grouard G, Durand I, Filgueira L, Banchereau J, Liu Y-J (1996) Dendritic cells capable of stimulating T cells in germinal centres. Nature 384:364
22. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J (1996) Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape (see Comments). Science 274:1363
23. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Mellon S, Shanafelt A, Muench M, Kelner G, Namikawa R, Rennick D, Roncarolo M-G, Zlotnick A, Rosnet O, Dubreuil P, Birnbaum D, Lee F (1994) Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368:643
24. Hoglund P, Sundback J, Olsson-Alheim MY, Johannson M, Salcedo M, Ohlen C, Ljunggren HG, Sentman CL, Karre K (1997) Host MHC class I gene control of NK-cell specificity in the mouse. Immunol Rev 155:11
25. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M (1999) Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161:777
26. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52
27. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961
28. Ishida T, Oyama T, Carbone DP, Gabrilovich DI (1998) Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 161:4842
29. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR (1998) Major histocompatibility complex I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 188:409
30. Lebsack ME, McKenna HJ, Hoek JA, Hanna R, Feng A, Maraskovsky E, Hayes FA (1997) Safety of flt3 ligand in healthy volunteers. Blood 90:170a
31. Lee DS, White DE, Hurst R, Rosenberg SA, Yang JC (1998) Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2 based immunotherapy (see Comments). Cancer J Sci Am 4:86
32. Lyman SD, Jacobsen SEW (1998) c-kit ligand and Flt3 ligand: stem progenitor cell factors with overlapping yet distinct activities. Blood 91:101
33. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FF, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP (1993) Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell 75:1157
34. Lyman SD, Brasel K, Rousseau AM, Williams DE (1994) The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor. Stem Cells 12:99
35. Lyman SD, James L, Johnson L, Brasel K, Vries P de, Escobar SS, Downey H, Splett RR, Beckmann MP, McKenna HJ (1994) Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 83:2795
36. Lyman SD, James L, Escobar S, Downey H, Vries P de, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS, Jenkins NA, Belmont JW, Davison BL (1995) Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene 10:149
37. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625
38. + T cells. J Immunol 154:5071
39. Mackey MF, Gunn JR, Maliszewski C, Kikutani H, Noelle RJ, Barth, Jr. (1998) Dendritic cells require maturation via CD40 to generate protective antitumor immunity, J Immunol 161:2094
40. Maloney DG (1998) Advances in immunotherapy of hematologic malignancies. Curr Opin Hematol 5:237
41. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 184:1953
42. Maraskovsky E, Roux E, Teepe M, Braddy S, Hoek J, Lebsack M, McKenna HJ (1997) Flt3 ligand increases peripheral blood dendritic cells in healthy volunteers. Blood 90:580a
43. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR (1991) A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65:1143
44. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK (1999) Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59:56
45. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells (see Comments). Nat Med 4:328
46. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075
47. Park JA, Wang E, Kurt RA, Schluter SF, Hersh EM, Akporiaye ET (1997) Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells. Cancer Gene Ther 4:42
48. Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK (1998) Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review (Editorial) Urol Res 26:155
49. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol 161:6164
50. Reichardt VL, Okada CY, Liso A, Benike CJ Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R (1999) Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study (in Process Citation). Blood 93:2411
51. + progenitors in human bone marrow. J Immunol 149:2681
52. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D (1991) Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSFIR family. Oncogene 6:1641
53. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413
54. Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109
55. Saunders D, Lucas K, Ismaili J, Wu L, Maraskovsky E, Dunn A, Shortman K (1996) Dendritic cell development in culture from thymic precursor cells in the absence of granulocyte/macrophage colony-stimulating factor. J Exp Med 184:2185
56. Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL (1998) Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol 161:2817
57. Shimizu K, Fields RC, Giedlin M, Mule JJ (1999) Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 96:2268
58. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91:459
59. Spellman JE, Gollnick SO, Zhang PJ, Tomasi TB (1996) Cytokine production by human soft tissue sarcomas: implications for immunosuppression within the tumour bed. Surg Oncol 5:237
60. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271
61. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? (see Comments). Nat Med 2:1361
62. Strobl H, Bello Fernandez C, Riedl E, Pickl WF, Majdic O, Lyman SD, Knapp W (1997) flt3 ligand in cooperation with transforming growth factor-beta1 potentiates in vitro development of Langerhans-type dentritic cells and allows single-cell dendritic cell cluster formation under serum-free conditions. Blood 90:1425
63. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK (1997) Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278:117
64. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A, Keikavoussi P, Kampgen E, Bender A, Schuler G (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223:1
65. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36:39
66. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486
67. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684
68. Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP (1998) Inhibition of angiogenesis by interleukin 4. J Exp Med 188:1039
69. Zitvogel L, Couderc B, Mayordomo JI, Robbins PD, Lotze MT, Storkus WJ (1996) IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann NY Acad Sci 795:284